A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC
Clinical trial NCT07432568 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07432568
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-09
- Primary completion
- 2032-06-09
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.